It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...

Explore the impact of Central Bank Digital Currencies (CBDCs), their role in modern economies, and why countries are rapidly adopting digital money solutions.